This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Depression was sold to us as a simple problem of serotonin insufficiency, a convenient narrative that made drug companies like Eli Lilly, Forest Pharmaceuticals, and Pfizer very rich. As a former pharmaceutical advertising writer, I not only witnessed the explosive growth in antidepressant drugs, I contributed to it.
SHOW MORE NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD. Sanom/Adobestock BREAKING NEWS A new formulation of ketamine is progressing through a novel US Food and Drug Administration review pathway, announced NRx Pharmaceuticals.
Stephenson and a team of researchers from various academic and pharmaceutical institutions, including the University of Virginia School of Medicine. Maelys Touya was an employee of Lundbeck LLC, and Lambros Chrones was an employee of Takeda Pharmaceuticals U.S.A., The study was authored by Judith J. Additionally, Anita H.
There was no placebo group, and all patients started on citalopram, manufactured by Lundbeck, which was motivated by horrendously erroneous claims of citalopram’s “absence of discontinuation symptoms” and its “safety” in elderly patients. Nothing in Insel’s narrative would harm psychiatry’s guild interests or pharmaceutical interests.
This turn to ketamine is occurring despite the fact that the Food and Drug Administration has repeatedly warned that the FDA has not approved ketamine for the treatment of any psychiatric disorder (though controversially approving esketamine nasal spray). accepting personal or office gifts or corporate donations from industry.
With the explosion of more and more drugs in cabinets across the country, more and more children are dying—but still, pharmaceutical companies push their products, leading to yet more drugs and yet more deaths. Unlike the pharmaceutical industry, in our village community the pain of losing a single child was felt by all.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content